Benchmark Initiates Coverage on 180 Life Sciences (NASDAQ:FRMM)

Equities research analysts at Benchmark began coverage on shares of 180 Life Sciences (NASDAQ:FRMM) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set a “speculative buy” rating and a $5.00 price target on the stock. Benchmark’s target price indicates a potential upside of 132.56% from the company’s current price.

Separately, Weiss Ratings initiated coverage on shares of 180 Life Sciences in a research note on Thursday. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

180 Life Sciences Price Performance

180 Life Sciences stock opened at $2.15 on Tuesday. 180 Life Sciences has a 12-month low of $2.15 and a 12-month high of $174.60. The company has a current ratio of 10.07, a quick ratio of 10.07 and a debt-to-equity ratio of 1.11.

180 Life Sciences (NASDAQ:FRMM) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($12.14) earnings per share (EPS) for the quarter. The company had revenue of $2.44 million for the quarter.

180 Life Sciences Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.